文献速递肿瘤 PET/CT

FDG-PET与FMISO-PET联合预测早期NSCLC立体定向放疗预后

Combination of FDG-PET and FMISO-PET as a treatment strategy for patients undergoing early-stage NSCLC stereotactic radiotherapy.
PubMed 文献 · EJNMMI Res · 2019-12-04

按FDG SUVmax 6.81和FMISO SUVmax 1.89阈值分三组,A组(双低)无复发,C组(双高)复发率70%,A与C组PFS差异显著(p<0.001)。联合双PET可识别基线复发风险。

要点

  • FDG与FMISO双PET联合可分层评估NSCLC SBRT后复发风险。
  • 双低组无复发,双高组复发率70%,PFS差异显著。
  • 肿瘤>2cm患者中,双高与双低组PFS仍有显著差异。

核心结论

  • FDG与FMISO PET联合可识别NSCLC患者SBRT前的基线复发风险,并提示是否需附加治疗以改善生存。

研究设计与样本

  • 患者中位年龄83岁,男性19例、女性13例;研究终点时23例(71.9%)无复发,9例(28.1%)复发。

主要发现

  • 复发组与非复发组在肿瘤直径和所有PET参数上均有显著差异,这些参数为全部患者复发的显著预测因子。
  • 在22例肿瘤>2cm患者中,肿瘤直径和FDG SUVmax不是显著预测因子。
  • 按FDG SUVmax 6.81和FMISO SUVmax 1.89阈值分为三组:A组(双低,n=14)无复发,B组(FDG高FMISO低,n=8)2例(25%)复发,C组(双高,n=10)7例(70%)复发。
  • Kaplan-Meier分析显示全部患者中A与B组PFS差异显著(p=0.013),A与C组差异显著(p<0.001)。
  • 在肿瘤>2cm患者中,A与C组PFS差异显著(p=0.002)。

关键数值与推荐

  • FDG SUVmax阈值6.81和FMISO SUVmax阈值1.89由ROC分析获得,用于划分复发风险和PFS评估。

临床怎么用

  • 对拟行SBRT的早期NSCLC患者,可考虑FDG与FMISO双PET联合评估基线复发风险。
  • 双高患者复发风险高,或需考虑附加治疗以改善生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We investigated the prognostic predictive value of the combination of fluorodeoxyglucose (FDG)- and fluoromisonidazole (FMISO)-PET in patients with non-small cell lung carcinoma (NSCLC) treated with stereotactic body radiation therapy (SBRT). PATIENTS AND METHODS: We prospectively examined patients with pathologically proven NSCLC; all underwent FDG and FMISO PET/CT scans before SBRT. PET images were acquired using a whole-body time-of-flight PET-CT scanner with respiratory gating. We classified them into recurrent and non-recurrent groups based on their clinical follow-ups and compared the groups' tumor diameters and PET parameters (i.e., maximum of the standardized uptake value (SUVmax), metabolic tumor volume, tumor-to-muscle ratio, and tumor-to-blood ratio). We performed univariate analysis to evaluate the impact of the PET variables on the patients' progression-free survival (PFS). We divided the patients by thresholds of FDG SUVmax and FMISO SUVmax obtained from receiver operating characteristic analysis for assessment of recurrence rate and PFS. RESULTS: Thirty-two NSCLC patients (19 male and 13 females; median age, 83 years) were enrolled. All received SBRT. At the study endpoint, 23 patients (71.9%) were non-recurrent and nine patients (28.1%) had recurrent disease. Significant between-group differences were observed in tumor diameter and all the PET parameters, demonstrating that those were significant predictors of the recurrence in all patients. In the 22 patients with tumors > 2 cm, tumor diameter and FDG SUVmax were not significant predictors. Thirty-two patients were divided into three patterns from the thresholds of FDG SUVmax (6.81) and FMISO SUVmax (1.89); A, low FDG and low FMISO (n = 14); B, high FDG and low FMISO (n = 8); C, high FDG and high FMISO (n = 10). No pattern A patient experienced tumor recurrence, whereas two pattern B patients (25%) and seven pattern C patients (70%) exhibited recurrence. A Kaplan-Meier analysis of all patients revealed a significant difference in PFS between patterns A and B (p = 0.013) and between patterns A and C (p < 0.001). In the tumors > 2 cm patients, significant differences in PFS were demonstrated between pattern A and C patients (p = 0.002). CONCLUSION: The combination of FDG- and FMISO-PET can identify patients with a baseline risk of recurrence and indicate whether additional therapy might be performed to improve survival.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Watanabe S, Inoue T, Okamoto S, et al. Combination of FDG-PET and FMISO-PET as a treatment strategy for patients undergoing early-stage NSCLC stereotactic radiotherapy. EJNMMI Res. 2019. PMID: 31802264. doi:10.1186/s13550-019-0578-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。